---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-038041"
form_type: "8-K"
ticker: "KNSA"
cik: "0001730430"
company_name: "Kiniksa Pharmaceuticals International, plc"
filed_at: "2025-04-23T23:59:59+00:00"
generated_at: "2026-05-23T08:18:15.250523+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Kiniksa approves KPL-387 LTIP for execs, grants PSUs and options tied to BLA submission and FDA approval

## Summary
- Compensation Committee approved KPL-387 Long-Term Incentive Plan for executive officers, linked to BLA submission (Milestone 1) and FDA approval (Milestone 2) for recurrent pericarditis treatment.
- CEO Sanj Patel granted 16,312 PSUs and 26,142 options; CFO Mark Ragosa granted 9,309 PSUs and 14,918 options.
- Awards include cash, PSUs, and options, with earnout percentages (100%, 75%, 50%, 0%) based on milestone achievement dates.
- If a change in control occurs, unvested awards may accelerate under specified conditions, including termination without cause or resignation for good reason.
- The plan covers five named executive officers; cash award amounts are based on base salary at milestone achievement.

## SEC filing metadata
- accession: 0001104659-25-038041
- form_type: 8-K
- ticker: KNSA
- cik: 0001730430
- company_name: Kiniksa Pharmaceuticals International, plc
- filed_at: 2025-04-23T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/0001104659-25-038041-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730430/000110465925038041/tm2512708d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-038041
- JSON: https://secwatch.observer/filing/0001104659-25-038041.json
- Plain text: https://secwatch.observer/filing/0001104659-25-038041.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.